Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

Presentation TCT 2025

TCT 498: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT2 Inhibitors on Cardiovascular Outcomes in Patients with Diabetes Undergoing Percutaneous Coronary Intervention

Presenter: Ahmed A. Mahmoud

October 28, 2025

Presentation TCT 2025

TCT 494: Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis

Presenter: Mehmet Cilingiroglu

October 28, 2025

Presentation TCT 2025

TCT 801: Comparative Efficacy and Safety of Beta Blockers Versus SGLT2 Inhibitors in Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA)

Presenter: Mehmet Cilingiroglu

October 27, 2025

Presentation TCT 2025

Emerging Therapies: The Role of GLP-1 Agonists and SGLT2 Inhibitors in PAD/CLTI Management. Impact on the Guidelines

Presenter: Marc P. Bonaca

October 27, 2025

Presentation TCT 2025

TCT 760: SGLT2 Inhibitors Reduce Acute Kidney Injury and Improve Survival in Diabetic Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Priyesh Thakurathi

October 27, 2025

Presentation TCT 2025

TCT 755: Impact of SGLT2 Inhibitors on Outcomes After TAVR: A Real-World Propensity-Matched Analysis

Presenter: Salman Zahid

October 27, 2025

Presentation TCT 2025

TCT 748: Effects of SGLT2 Inhibitors on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus Undergoing Transcatheter Mitral Valve Repair: A Propensity-Matched Analysis

Presenter: Mahmoud Abdelnabi

October 25, 2025

Presentation TCT 2025

TCT 749: Renal Protective Effects of SGLT2 Inhibitors After Transcatheter Mitral Valve Repair in Patients with Type 2 Diabetes Mellitus: A Propensity-Matched Retrospective Analysis

Presenter: Mahmoud Abdelnabi

October 25, 2025

Presentation NY Valves 2025

Impact of SGLT2 Inhibitors on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Tamari Lomaia

June 26, 2025

Presentation THT 2025

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 12, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation TCT 2024

TCT 304: SGLT2 Inhibitor Empagliflozin Before Coronary Angiography: Can We Reduce Patient Stress?

Presenter: Katica Cvitkusic Lukenda

October 27, 2024

Presentation TCT 2024

TCT 185: Clinical Outcomes of SGLT2 Inhibitors Among Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair

Presenter: Samarthkumar Thakkar

October 27, 2024

Presentation TCT 2023

Expanding Your Lane and Not Your Waist: Cardiologists and GLP1-RA/SGLT2i

Presenter: Eldrin Lewis

October 26, 2023

Presentation THT 2023

SGLT2 Inhibitors Have a Unique Mechanism That Accounts for Their Comprehensive Benefits

Presenter: Milton Packer

March 20, 2023

Presentation THT 2023

The Impact of SGLT2 Inhibitors Across the Spectrum of Heart Failure

Presenter: Scott Solomon

March 20, 2023

Presentation TCT 2022

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Marc Bonaca

September 17, 2022

Advertisement

TCT 498: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT2 Inhibitors on Cardiovascular Outcomes in Patients with Diabetes Undergoing Percutaneous Coronary Intervention

TCT 494: Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis

TCT 801: Comparative Efficacy and Safety of Beta Blockers Versus SGLT2 Inhibitors in Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA)

Emerging Therapies: The Role of GLP-1 Agonists and SGLT2 Inhibitors in PAD/CLTI Management. Impact on the Guidelines

TCT 760: SGLT2 Inhibitors Reduce Acute Kidney Injury and Improve Survival in Diabetic Patients Undergoing Transcatheter Aortic Valve Replacement

TCT 755: Impact of SGLT2 Inhibitors on Outcomes After TAVR: A Real-World Propensity-Matched Analysis

TCT 748: Effects of SGLT2 Inhibitors on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus Undergoing Transcatheter Mitral Valve Repair: A Propensity-Matched Analysis

TCT 749: Renal Protective Effects of SGLT2 Inhibitors After Transcatheter Mitral Valve Repair in Patients with Type 2 Diabetes Mellitus: A Propensity-Matched Retrospective Analysis

Impact of SGLT2 Inhibitors on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

TCT 304: SGLT2 Inhibitor Empagliflozin Before Coronary Angiography: Can We Reduce Patient Stress?

TCT 185: Clinical Outcomes of SGLT2 Inhibitors Among Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair

Expanding Your Lane and Not Your Waist: Cardiologists and GLP1-RA/SGLT2i

SGLT2 Inhibitors Have a Unique Mechanism That Accounts for Their Comprehensive Benefits

The Impact of SGLT2 Inhibitors Across the Spectrum of Heart Failure

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content